Transition of oncology programme into lead optimisation triggers EUR 2.0M milestone payment to Evotec

Download PDF Copy

Reviewed

Evotec AGJan 13 2011

Evotec AG (Frankfurt:EVT) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment of EUR 2.0 million to Evotec. The milestone reached was on the transition of an oncology programme into lead optimisation.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: "This is the eleventh milestone achieved as part of this alliance with Boehringer Ingelheim and the second against an oncology target. We continue to enjoy a very rich scientific partnership with Boehringer Ingelheim and look forward to continued success through our joint project teams in the coming years."

Source:

Evotec AG

Posted in: Medical Research News | Medical Condition News

Comments (0)

Download PDF Copy

Suggested Reading

Study urges significant investment in cancer research in poorer nations

Osimertinib plus chemotherapy offers overall survival advantage for patients with EGFR-mutated advanced NSCLC

New tool helps identify risky medications for older cancer patients

Urine test identifies three biomarkers for accurate prostate cancer detection

Artificial intelligence set to transform mental health care for breast cancer patients

Study provides evidence for a causal genetic link between prostate cancer and urothelial carcinoma

MicroRNA panels show promise for improving prostate cancer diagnosis

Breakthrough discovery reveals treatable form of familial mesothelioma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.